Humalog 100 IU/1mL Cartridge
Focus Express Mail Pharmacy carries a large inventory of insulin, syringes, and pen needles from all of the major manufacturers. Enroll now to see how you can get the items that YOU need for little or no cost!
Humalog® 100 IU/1mL Cartridge
Humalog® 100 IU/1mL is an insulin analog that is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. Humalog® has a more rapid onset and a shorter duration of action than Regular human insulin. Therefore, in patients with type 1 diabetes, Humalog® should be used in regimens that include a longer–acting insulin. However, in patients with type 2 diabetes, Humalog® may be used without a longer–acting insulin when used in combination therapy with sulfonylurea agents.
Humalog® may be used in an external insulin pump, but should not be diluted or mixed with any other insulin when used in the pump
Humalog® is intended for subcutaneous administration, including use in select external insulin pumps. Dosage regimens of Humalog® will vary among patients and should be determined by the healthcare provider familiar with the patient's metabolic needs, eating habits, and other lifestyle variables. Pharmacokinetic and pharmacodynamic studies showed Humalog® to be equipotent to Regular human insulin (i.e., one unit of Humalog® has the same glucose-lowering effect as one unit of Regular human insulin), but with more rapid activity. The quicker glucose-lowering effect of Humalog® is related to the more rapid absorption rate from subcutaneous tissue. An adjustment of dose or schedule of basal insulin may be needed when a patient changes from other insulin to Humalog®, particularly to prevent pre-meal hyperglycemia.
When used as a meal-time insulin, Humalog® should be given within 15 minutes before or immediately after a meal. Regular human insulin is best given 30 to 60 minutes before a meal. To achieve optimal glucose control, the amount of longer–acting insulin being given may need to be adjusted when using Humalog®.
The rate of insulin absorption and consequently the onset of activity are known to be affected by the site of injection, exercise, and other variables. Humalog® was absorbed at a consistently faster rate than Regular human insulin in healthy male volunteers given 0.2 U/kg Regular human insulin or Humalog® at abdominal, deltoid, or femoral sites, the three sites often used by patients with diabetes. When not mixed in the same syringe with other insulin, Humalog® maintains its rapid onset of action and has less variability in its onset of action among injection sites compared with Regular human insulin. After abdominal administration, Humalog® concentrations are higher than those following deltoid or thigh injections. Also, the duration of action of Humalog® is slightly shorter following abdominal injection, compared with deltoid and femoral injections. As with all insulin preparations, the time course of action of Humalog® may vary considerably in different individuals or within the same individual.
The manufacturer is Eli Lilly and Company.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.